Telix Pharmaceuticals is trading 5.92% down now at A$13.66 after extending its decline following the October 21 quarterly update.
- Third-quarter revenue was US$245 million, up 19% year over year but down 1% from the prior quarter.
- Investors are also weighing the planned US$1.65 billion ITM acquisition, partly funded with Telix shares.
- Telix reaffirmed its 2026 revenue outlook, making the update mixed rather than a clear guidance cut.